GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Rare instances of vaccine side-effects must not be used to “undermine the vital public health role that vaccination plays in keeping people safe from disease”, the UK Covid-19 Inquiry has heard.

GlaxoSmithKline and CureVac are to begin developing a next generation vaccine targeting emerging variants of the coronavirus – although it is unlikely to be ready until at least next year.

British drugmaker GSK plans to acquire US biotech firm IDRx for $1.15 billion, focusing on innovative tumour treatments. Meanwhile, Moderna cuts sales forecast due to weak vaccine demand, and J&J ...

A possible new coronavirus vaccine candidate produced by Sanofi and GSK (GlaxoSmithKline) that uses the human body’s own antigens to neutralize antibody responses for people who have already ...

Former GlaxoSmithKline chief executive Sir Andrew Witty has taken a leave of absence from his current day job to lead the push to develop vaccines for COVID-19 at the World Health Organization (WHO).

Teva Pharmaceutical Industries Ltd. ADR 0.46% $24.53B ...

Pfizer (PFE) and BioNTech (BNTX), the developers of the COVID-19 vaccine ... Pfizer (PFE) and GSK (GSK) offer Abrysvo and Arexvy vaccines for RSV, respectively, Moderna (NASDAQ:MRNA) recently ...

Vaccine makers face a demand cliff as coronavirus vaccines wane, but these stocks are more than meets the eye.

MRNACR-04 is under clinical development by GSK and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a ...